Results 101 to 110 of about 4,931,245 (245)
Movement Disorders Clinical Practice, EarlyView.
Bruno Antunes Contrucci +10 more
wiley +1 more source
Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's disease (PD) is the second most common neurodegenerative disease. Symptomatic treatment is based on dopaminergic replacement. With disease progression, the initial benefit of levodopa becomes inconsistent, and motor complications emerge.
Elena Ojeda‐Lepe +15 more
wiley +1 more source
, 2015 Hongjuan Shi,1,2,* Xinxin Yang,2,3,* Hui Zhao,4 Shenyang Zhang,2 Jie Zu,2 Wei Zhang,2 Xia Shen,2 Guiyun Cui,2,3 Fang Hua,2,3 Chuanzhu Yan1 1Department of Neurology, Qilu Hospital of Shangdong University, Jinan, 2Department of Neurology, Affiliated ...
Yang X +9 more
core
Exercise and Motor Complications in Parkinson's Disease: A Systematic Review and Meta‐Analysis
Movement Disorders Clinical Practice, EarlyView.Abstract Background Levodopa remains the most effective pharmacological treatment for Parkinson's disease (PD), but long‐term use commonly leads to motor complications such as levodopa‐induced dyskinesia (LID) and motor fluctuations, significantly contributing to disability. Exercise is well‐established for improving motor and non‐motor symptoms in PD;
Priscila Nóbrega‐Sousa +5 more
wiley +1 more source
Dyskinesia Induced By Phenytoin.
, 2015 Phenytoin is an effective antiepileptic drug, although, it can be associated with many side effects, including dyskinesia. To describe the clinical characteristics of phenytoin induced dyskinesia.
Scotoni, A E, Montenegro, M A, Cendes, F
core
Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
Brain Sciences, 2019 Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS).
Gloria Martí-Andrés +6 more
doaj +1 more source
Severe Lower Limb and Abdominal Edema Associated with Subcutaneous Apomorphine Infusion
Movement Disorders Clinical Practice, EarlyView.
Guillaume Costentin, David Maltête
wiley +1 more source
A Gap Analysis of Deep Brain Stimulation for Childhood‐Onset Movement Disorders
Movement Disorders, EarlyView.Abstract Background Deep brain stimulation (DBS) is an established and increasingly utilized therapy for childhood‐onset movement disorders. However, pediatric DBS poses unique challenges that are not adequately addressed by adult‐derived paradigms. Objective To identify key gaps in the current use of DBS in childhood‐onset movement disorders and to ...
Daniela Munoz‐Chesta +6 more
wiley +1 more source
Decoding Finely Tuned Gamma Oscillations in Chronic Deep Brain Stimulation for Parkinson's Disease
Movement Disorders, EarlyView.Abstract Background Finely tuned Gamma (FTG) activity—spontaneous narrowband Gamma oscillations (sFTG) or entrained to half the stimulation frequency (eFTG)—is typically linked to on‐medication states and dyskinesia in Parkinson's disease (PD), making it a potential physiomarker for adaptive deep brain stimulation (aDBS).
Marjolein Muller +8 more
wiley +1 more source
Why Use Immersive Virtual Reality to Assess Gait in Functional Motor Disorders?
Movement Disorders, EarlyView.Abstract Background Functional motor disorders (FMD) are disabling conditions modulated by attentional demands. Immersive virtual reality (iVR) engages multiple attentional and sensory networks, but its application in people with FMD (PwFMD) remains limited.
Marialuisa Gandolfi +14 more
wiley +1 more source